Cationic trypsinogen mutations and pancreatitis
- PMID: 15749231
- DOI: 10.1016/j.cll.2004.12.004
Cationic trypsinogen mutations and pancreatitis
Abstract
The discovery of PRSS 1 mutations in hereditary pancreatitis and analysis of how the genotype affects the presentation and progression of hereditary pancreatitis has led to a better understanding of the pathophysiology of the disease. Patients with hereditary pancreatitis present with symptoms at an early age and have a significant lifetime risk for the development of endocrine and exocrine insufficiency, albeit at a later stage than patients with either idiopathic or alcoholic chronic pancreatitis. There are distinct phenotypic differences between hereditary pancreatitis and with other types of pancreatitis. As many as 80% of patients with symptomatic hereditary pancreatitis have an underlying causative PRSS1 mutation; there are, however, few significant phenotypic differences between these PRSS1 mutations. TheR122H mutation is the most common PRSS1 mutation observed, and patients with the R122H mutation present earlier. This, however, does not necessarily translate into a more aggressive disease with respect to complications of chronic pancreatitis. Indeed, the age of presentation of symptoms may be a poor surrogate for predicting outcome, as inherited disorders of trypsinogen may cause subclinical attacks of pancreatitis, which ultimately lead to pancreatic destruction and dysfunction. All patients, irrespective of whether they carry a PRSS1 mutation, are at significant risk of developing pancreatic ductal adenocarcinoma. The risk appears to be insignificant below the age of 40 years, but it increases incrementally thereafter. Significantly, the risk of pancreatic cancer is not related to PRSS1 mutation type and does not appear to be related to the mode of inheritance. The role of SPINK1 mutations in modifying the expression of PRSS1mutations is unclear but appears to be of clinical importance. It is unlikely that they act as causative mutations per se, at least in the Western form of the disease. Additionally, they do not appear to have an impact on the penetrance of PRSS1 gene mutations in hereditary pancreatitis.
Similar articles
-
Cationic trypsinogen mutations and pancreatitis.Gastroenterol Clin North Am. 2004 Dec;33(4):767-87. doi: 10.1016/j.gtc.2004.07.003. Gastroenterol Clin North Am. 2004. PMID: 15528017 Review.
-
CFTR, PRSS1 and SPINK1 mutations in the development of pancreatitis in Brazilian patients.JOP. 2003 Sep;4(5):169-77. JOP. 2003. PMID: 14526128
-
The course of genetically determined chronic pancreatitis.JOP. 2003 Jul;4(4):146-54. JOP. 2003. PMID: 12853682
-
Screening for human cationic trypsinogen (PRSS1) and trypsinogen inhibitor gene (SPINK1) mutations in a Finnish family with hereditary pancreatitis.Scand J Gastroenterol. 2007 Aug;42(8):1000-5. doi: 10.1080/00365520701206738. Scand J Gastroenterol. 2007. PMID: 17613931
-
Hereditary chronic pancreatitis.Best Pract Res Clin Gastroenterol. 2008;22(1):115-30. doi: 10.1016/j.bpg.2007.10.019. Best Pract Res Clin Gastroenterol. 2008. PMID: 18206817 Review.
Cited by
-
Constitutive IKK2 activation in acinar cells is sufficient to induce pancreatitis in vivo.J Clin Invest. 2007 Jun;117(6):1502-13. doi: 10.1172/JCI30876. Epub 2007 May 24. J Clin Invest. 2007. PMID: 17525799 Free PMC article.
-
Current status of molecular markers for early detection of sporadic pancreatic cancer.Biochim Biophys Acta. 2011 Jan;1815(1):44-64. doi: 10.1016/j.bbcan.2010.09.002. Epub 2010 Oct 1. Biochim Biophys Acta. 2011. PMID: 20888394 Free PMC article. Review.
-
Differential gene expression analysis of peripheral blood mononuclear cells reveals novel test for early detection of pancreatic cancer.Cancer Biomark. 2011-2012;11(1):1-14. doi: 10.3233/CBM-2012-0260. Cancer Biomark. 2011. PMID: 22820136 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials